Axsome Therapeutics, Inc.
A maker of medicines for brain and nervous-system conditions, Axsome Therapeutics sells FDA-approved drugs including AUVELITY for depression, SUNOSI for excessive daytime sleepiness in narcolepsy and sleep apnea, and SYMBRAVO for acute migraine. Founded in 2012 by physician Herriot Tabuteau, the company got its start in a tiny windowless office in New York's Rockefeller Center that the team affectionately nicknamed "the broom closet." It now also works on experimental treatments for Alzheimer's-related agitation and other neurological disorders.
Granted 573.7K · Sold 573.7K
Granted 99.9K · Bought 30.1K · Sold 93.8K
Granted 193.1K · Bought 4.0K · Sold 143.1K
Granted 60.0K · Bought 42.2K · Sold 60.0K
Granted 59.1K · Bought 6.8K · Sold 57.7K
Bought 1.0K
Granted 15.0K · Sold 15.0K
Granted 36.0K · Sold 36.0K
Granted 1.4K · Sold 600
Granted 241.9K · Sold 241.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Tabuteau HerriotChief Executive Officer, Director, 10% owner · 35 transactions | — | 7.35M | 573.7K | — | 573.7K |
| Coleman MarkDirector · 37 transactions | — | 434.2K | 99.9K | 30.1K | 93.8K |
| Jeffs RogerDirector · 26 transactions | — | 58.4K | 193.1K | 4.0K | 143.1K |
| Pizzie NickChief Financial Officer · 19 transactions | — | 43.4K | 60.0K | 42.2K | 60.0K |
| Saad Mark EDirector · 15 transactions | — | 12.0K | 59.1K | 6.8K | 57.7K |
| Kaye RandallChief Medical Officer · 2 transactions | — | 11.0Kas of Dec 2015 | — | 1.0K | — |
| Maizel AriChief Commercial Officer · 4 transactions | — | 7.5K | 15.0K | — | 15.0K |
| Murdock Hunter R.General Counsel · 10 transactions | — | 6.0Kas of Jun 2025 | 36.0K | — | 36.0K |
| Ames ConstanceVice President, Finance · 1 transaction | — | 4.4Kas of Nov 2015 | — | — | — |
| Mahony SusanDirector · 3 transactions | — | 829 | 1.4K | — | 600 |
| Jacobson Mark L.Chief Operating Officer · 24 transactions | — | 233 | 241.9K | — | 241.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -1.14M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.